Compare Diamondback Energy Inc (FANG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Merck & Co., Inc. — how do they compare? Diamondback Energy Inc trades at $190.58 (market cap $53.38B), while Merck & Co., Inc. trades at $127.72 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 5.7× Diamondback Energy Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| FANG | MRK | |
|---|---|---|
Market Cap | $53.38B | $305.29B |
Sector | Energy | Health |
52-Week High | $213.69 | $129.52 |
52-Week Low | $134.53 | $77.60 |
Enterprise Value | $67.11B | $348.71B |
Dividend Yield | 2.32% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.28, up 0.31% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue growth remains robust. The company maintains solid cash flow from operations and a manageable debt-to-asset ratio of 22.26% as of 2025. A dividend of $1.10 was recently declared, with the next earnings report scheduled for August 3, 2026.
FANG presents a favorable outlook with a consensus price target of $234.50, implying 22.6% upside, supported by 90% buy ratings from analysts. Risks include volatile oil prices, geopolitical factors affecting energy markets, and declining net income margins. The stock's high P/E ratio of 193.63 warrants caution, but strong operational cash flow and institutional bullishness provide a solid foundation for growth-oriented investors.
MRK's stock trades at $128.08, up 6.02% over the past day, reflecting strong momentum. The technical outlook is bullish based on moving averages, with key support at $121 and resistance at $126. Fundamentally, the company reported $65.01B in 2025 revenue with a net income margin of 13.59%, and recent earnings beats in Q3 2025 and Q4 2025 highlight operational strength. The pending acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, signaling strategic growth initiatives.
The investment outlook for MRK is positive, supported by analyst consensus with a $137.30 price target and 67.57% buy ratings. Key opportunities include robust profitability and pipeline expansion via M&A, while risks involve rising debt levels and competitive pressures in the pharmaceutical sector. Earnings growth and successful integration of acquisitions are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
